Recent advances have been made in the understanding of the components and actions of the renin-angiotensin-aldosterone-system (RAAS), including the activity of renin receptors and the role of the RAAS in the regulation of cardiovascular and renal function. These advances firmly establish the RAAS as an expanding therapeutic target in patients with hypertension. Despite this progress, however, a complete understanding of the multiple target sites within the RAAS pathway, and its implications on treatment, are not fully understood. Post-program evaluation surveys and communications with experts have shown an educational need among clinicians to further understand the optimization of treatments that target the RAAS, its effects on outcomes in patients with HTN, and current registry data on achieving BP goals.